Trial resultsH2 2026a window, not a day
IMpactMF Phase 3 interim analysis (overall survival) in relapsed/refractory myelofibrosis
Geron expects to report results from its Phase 3 study of imetelstat (RYTELO) for JAK-inhibitor relapsed/refractory intermediate-2/high-risk myelofibrosis in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
DetailsClinical trial results · also called: readout / topline data
- Company
- Geron Corporation GERN
- Drug
- imetelstat (RYTELO)
- For
- JAK-inhibitor relapsed/refractory intermediate-2/high-risk myelofibrosis
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H2 2026 · the company gave a window, not a day; the calendar never invents one
- Source note
- Prior guidance placed the interim OS analysis in 2H 2026; on the Q2 2026 call management said projected timelines are unchanged but it is evaluating a modification to the interim event threshold, calls a positive interim an upside scenario, and keeps final OS analysis in 2H 2028 as base case. Timing risk is real.
- Checked
- Checked by a person when it was added
Check the sourcesdon’t take our word for it
- Source: fool.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- GERN headlines on this site
Geron Corporation
1 upcoming · 2 past catalysts
More from GERN